New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
06:38 EDTWCRX, ENDP, COV, VRX, TEVAFidelity Investments wants an Endo Health Solution's sale, Bloomberg reports
Fidelity Investments, Endo Health Solutions's (ENDP) largest shareholder, wants a sale, sources say, reports Bloomberg. It may be the company's best hope at regaining investor confidence after losing more than $1B in market value, or to undo the acquisitions that built the company. Endo has the lowest valuation in the U.S. specialty pharmaceuticals industry, according to Bloomberg data. On average, analysts see Endo getting at least a 26% premium in a deal. Teva Pharmaceutical Industries (TEVA) or Covidien Plc (COV) could go after parts or all of Endo, according to Stifel Financial Corp. Gabelli & Co. said Endo could break up or sell its pain drugs to Warner Chilcott Plc (WCRX) or Valeant Pharmaceuticals International (VRX). Reference Link
News For ENDP;TEVA;COV;WCRX;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
March 16, 2015
07:31 EDTENDPEndo announces launch of Natesto
Endo Pharmaceuticals, a subsidiary of Endo, announced the commercial availability of NATESTO, the first and only nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism. NATESTO was approved by the FDA in May 2014 for replacement therapy in adult men with conditions associated with deficiency or absence of endogenous testosterone, including primary hypogonadism or hypogonadotropic hypogonadism. NATESTO™ reduces the risk of transference via intranasal application.
March 13, 2015
15:50 EDTVRXValeant announces HSR clearance for acquisition of Salix
Valeant Pharmaceuticals (VRX) announced that it has received early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to its proposed acquisition of Salix Pharmaceuticals (SLXP). The expiration of the waiting period satisfies one of the conditions to consummate the tender offer and Valeant expects to be in the position to close the transaction on April 1.
13:46 EDTENDP, VRXValeant to raise Salix bid above $160 per share after Endo entry, NYT says
In response to Endo (ENDP) making a rival bid for Salix (SLXP), Valeant Pharmaceuticals (VRX) now plans to team up with Bill Ackman's Pershing Square and other top shareholders to raises its bid for Salix to above $160 per share, all in cash, according to The New York Times, citing people briefed on the matter. The exact price of Valeant’s raised offer was not yet known, the report stated. Salix shares are down about 1% to $168.88 in afternoon trading. Reference Link
13:43 EDTVRX, ENDPValeant seen hiking Salix bid above $160 per share cash, NYT says
Subscribe for More Information
10:51 EDTTEVA, ENDPOptions with increasing implied volatility
Options with increasing implied volatility: PVA BBEP SLXP ENDP MYL BBBY TEVA ZTS
08:15 EDTVRXAckman says shares of Valeant 'very cheap'
Subscribe for More Information
08:14 EDTENDP, VRXAckman says does not view Endo bid for Salix as credible
Subscribe for More Information
08:13 EDTVRX, ENDPAckman says Endo would be very highly levered with Salix deal
Bill Ackman of Pershing Square is speaking on CNBC.
08:11 EDTVRXAckman says Valeant CEO will not overpay for Salix
Bill Ackman of Pershing Square is speaking on CNBC.
05:47 EDTTEVAStocks with implied volatility movement; SLXP MNKD
Stocks with implied volatility movement; Salix (SLXP) 20, Teva (TEVA) 27 according to iVolatility.
March 12, 2015
16:01 EDTTEVAOptions Update; March 12, 2015
Subscribe for More Information
12:49 EDTTEVAWHO recommends tenofovir or entecavir for hepatitis B treatment
The World Health Organization issued its first-ever guidance for the treatment of chronic hepatitis B. Its recommended medicines consist of Gilead's (GILD) tenofovir or Bristol-Myers' (BMY) entecavir. Teva (TEVA) has FDA approval for generic entecavir.
11:38 EDTTEVATeva volatility increases on share price rally
Subscribe for More Information
11:29 EDTVRX, ENDPEndo repeats FY15 adjusted EPS view $4.35-$4.55, consensus $4.48
Subscribe for More Information
11:14 EDTTEVAPiper Jaffray biopharm analyst analyst/industry conference call at 12 pm
***TIME CHANGED TO 12pm from 11am on March 12***Biopharmaceuticals Analyst Schimmer, along with Dr. Bianca Weinstock-Guttman, discuss the current and future treatment paradigm and practice dynamics in MS on an Analyst/Industry conference call to be held on March 12.
11:12 EDTVRXOptions with increasing implied volatility
Subscribe for More Information
08:11 EDTENDP, VRXEndo offer for Salix unlikely to trump Valeant, says Leerink
Leerink believes Endo (ENDP) is unlikely to win the acquisition of Salix (SLXP) since Valeant's (VRX) offer is in all cash and Endo's shares sold off on the news, lessening the value of its buyout proposal. The firm says the estimated deal accretion of 15%-20% may not be enough to push up Endo's stock price.
08:09 EDTTEVATeva Mylan combination problematic for now, says Bernstein
Subscribe for More Information
07:57 EDTENDP, VRXValeant bid for Salix superior to Endo offer, says Canaccord
Subscribe for More Information
05:55 EDTVRX, TEVAStocks with implied volatility movement; TEVA VRX
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use